knowledge -WSS

knowledge

author：knowledge 2025-09-29 19:57:34 - browse：4

Coronary medical stent -- health business coverage from STAT — Adobe

Coronary stenting is, by some measures, the most overused procedure in hospitals. The problem costs the health system millions and unnecessarily exposes patients to risks of blood clots, torn arteries, infections, and other life-threatening injuries.

In 2020, Medicare started paying physicians to place stents, balloons, and perform other procedures designed to open clogged coronary arteries outside of hospitals, in less expensive outpatient settings. It didn’t take long for private equity firms to catch on. They’ve been racing to buy up cardiology practices ever since, rolling them into bigger and bigger chains with an eye toward reselling them at a profit.

It’s similar to what happened with orthopedics and gastroenterology, two specialties that have become saturated with private equity money since more procedures went outpatient. Research in other specialties has shown that these financial investors tend to usher in more patients, ramp up surgeries, and jack up prices, effectively increasing spending even as government policies try to lower it. Now, experts say they fear the same thing could happen in cardiology, a field with a long track record of overuse.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Q&A: Jennifer Adair on making gene therapy available globally

entertainment

WSS

Experts study whether long Covid risk adds up with each reinfection

Cholera vaccine supply gets boost as demand surges globally

Flu, Covid vaccination rates decline, new survey data show

More tobacco lobbyists active in statehouses

After traumatic brain injury, life support decisions can use more time

H5N1 bird flu virus started spreading in cows in Texas in December

leisure time

knowledge

entertainment

Supreme Court strikes down use of affirmative action

The biotech scorecard for Q4: 16 stock

Affirmative action in medical school literally saved lives

Close Medicare's dangerous gaps in addiction treatment coverage

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Medicare proposal to cover medical devices draws a mixed reaction

The stability of $0 premiums in Medicare Advantage

Trump demands the U.S. pay no more for drugs than other countries … again

UnitedHealth financials solid despite Change Healthcare cyberattack

Wikipedia

6 solutions to address cancer drug shortages and others

Cue Health's Covid

Study points to new risk in gene therapy death of Terry Horgan

WHO recommends second malaria vaccine

After traumatic brain injury, life support decisions can use more time

What will Novo Nordisk's VC do with its influx of cash?

hotspot

entertainment

knowledge

explore